HC Wainwright Issues Positive Outlook for AC Immune Earnings

AC Immune (NASDAQ:ACIU) – Analysts at HC Wainwright raised their FY2026 earnings estimates for AC Immune in a research report issued on Monday, March 16th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($0.87) for the year, up from their previous estimate of ($0.88). The consensus estimate for AC Immune’s current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for AC Immune’s FY2028 earnings at $1.07 EPS, FY2029 earnings at $1.52 EPS and FY2030 earnings at $1.61 EPS.

Other equities research analysts have also issued reports about the company. Jefferies Financial Group restated a “buy” rating and issued a $7.00 price target on shares of AC Immune in a research report on Friday, March 13th. Wall Street Zen upgraded AC Immune from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of AC Immune in a research note on Wednesday, January 21st. Finally, BTIG Research restated a “buy” rating and issued a $8.00 target price on shares of AC Immune in a report on Monday. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $9.00.

AC Immune Price Performance

ACIU opened at $3.09 on Wednesday. The firm has a market capitalization of $314.47 million, a price-to-earnings ratio of -3.68 and a beta of 1.64. The company’s 50 day simple moving average is $3.13 and its two-hundred day simple moving average is $3.05. AC Immune has a 1-year low of $1.43 and a 1-year high of $4.00.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings data on Friday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.01. The company had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $1.14 million. AC Immune had a negative net margin of 1,977.71% and a negative return on equity of 103.15%.

Institutional Trading of AC Immune

Several hedge funds have recently made changes to their positions in the company. EFG International AG acquired a new stake in shares of AC Immune during the 4th quarter worth approximately $41,000. Private Advisor Group LLC purchased a new stake in shares of AC Immune during the 3rd quarter valued at approximately $48,000. Goldman Sachs Group Inc. lifted its holdings in AC Immune by 46.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock valued at $58,000 after acquiring an additional 5,920 shares during the last quarter. Susquehanna International Group LLP acquired a new position in AC Immune in the third quarter valued at approximately $63,000. Finally, Sei Investments Co. purchased a new position in AC Immune in the second quarter worth approximately $51,000. Hedge funds and other institutional investors own 51.36% of the company’s stock.

More AC Immune News

Here are the key news stories impacting AC Immune this week:

• Positive Sentiment: Zacks upgraded AC Immune to a Buy (Zacks Rank #2), citing improved earnings prospects — this upgrade can attract buying interest from momentum and quant investors. AC Immune (ACIU) Upgraded to Buy
• Positive Sentiment: BTIG Research issued a Buy rating for ACIU, which may support near‑term demand from institutional traders. AC Immune Earns Buy Rating from BTIG Research
• Positive Sentiment: Brokerage consensus price target reported at $9 — substantially above the current trade and a potential catalyst if investors believe upside to fair value. AC Immune Receives $9.00 Consensus Price Target
• Neutral Sentiment: HC Wainwright issued quarterly FY2026 estimates (Q1–Q4) of ($0.22) per share — confirms near‑term loss expectations and provides a predictable earnings cadence. HC Wainwright Q‑Quarter Estimates
• Neutral Sentiment: Zacks published a sector‑comparison piece on ACIU vs. peers; useful for context but less likely to move the stock by itself. Is AC Immune Outperforming Other Medical Stocks?
• Neutral Sentiment: Reported short‑interest data appears to show 0 shares and NaN changes (days‑to‑cover 0.0) — data inconsistency makes it unreliable as a short‑squeeze signal today.
• Negative Sentiment: HC Wainwright trimmed multi‑year EPS forecasts: FY2028 lowered from $1.30 to $1.07 and FY2029 from $1.90 to $1.52 — reductions that temper longer‑term upside and reflect increased model uncertainty. HC Wainwright Lowers FY2028/2029 Estimates

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.